Ziska Pharmaceuticals

What Ziska Pharmaceuticals does

Ziska Pharmaceuticals Limited is a Bangladesh-based, privately held pharmaceutical manufacturer founded in 1989, operating from its corporate headquarters in Dhaka and a manufacturing facility in Gazipur. The company produces generic and branded medicines across three principal therapeutic lines — general medicines (NSAIDs, antibiotics, cardiovascular, dermatology, and nutritionals), oncology and biotechnology (including targeted therapies such as sotorasib, palbociclib, selpercatinib, lenvatinib, and a pembrolizumab biosimilar), and hormonal therapeutics. Manufacturing is organized into four dedicated units — Solid Unit, Sterile Unit, Oncology & Biotech Unit, and Hormone Unit — supporting both domestic Bangladesh distribution and dedicated export channels, with several oncology and biotech products labeled 'Export Only' and shipped via DHL, EMS, FedEx, and TNT. The company is led by Managing Director Aminul Islam Khan alongside co-founders Monirul Khan and Zahirul Khan, and the company claims 35+ years of operation, a portfolio of 218+ branded products, and 40+ first-in-Bangladesh launches.

The business model is straightforward B2B pharmaceutical manufacturing: products are sold via direct order placement through the company website, through a domestic distribution network, and through export operations targeting international markets. Pricing is not publicly disclosed and is quote-based, consistent with typical pharma B2B contracting. The company serves healthcare providers, pharmacies, hospitals, and end-use patients across Bangladesh and multiple export geographies, with no named large-anchor customers and no disclosed revenue figures, funding rounds, or external institutional ownership in the source data. The 'Step Into Innovation' positioning and aggressive first-in-Bangladesh launch cadence indicate an R&D-active, product-led growth posture, though no AI, digital health, or software-platform components are present in the product or technology stack.

Name

Ziska Pharmaceuticals

Legal name

Ziska Pharmaceuticals Limited

Website

https://ziskapharma.com

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Ziska Pharmaceuticals is a Bangladesh-based, privately held pharmaceutical manufacturer founded in 1989 that produces 218+ generic and branded medicines across general, oncology/biotech, and hormone therapeutic categories, selling to healthcare providers domestically and exporting targeted oncology and biosimilar products globally.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Small-Molecule Generics (Branded/Unbranded) (HLAIABAA), Oncology Specialty Pharmaceuticals (HLAIACAA), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Generic pharmaceutical manufacturing
• Oncology biosimilars
• Hormone production
• Sterile injectables
• Pharmaceutical exports

Headquarters

HQ city

Dhaka

HQ country

Bangladesh

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Primary revenue stream from manufacturing and selling pharmaceutical products including generic drugs, specialty medications in oncology, biotech, and hormonal therapeutic areas. Products are sold both domestically in Bangladesh and exported to international markets.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Ziska Pharmaceuticals Limited manufactures and sells a broad portfolio of generic pharmaceutical products across multiple therapeutic categories, including general medicines, oncology & biotech products, and hormone products. The company operates dedicated manufacturing units for solid dosage, sterile injectables, oncology & biotech, and hormone formulations, producing over 218 marketed products with 35+ years of experience in the Bangladesh pharmaceutical market.

Product overview

Ziska Pharmaceuticals Limited is one of the leading pharmaceutical companies in Bangladesh with over 35 years of experience. The company operates a diversified portfolio of 218+ pharmaceutical products across three main therapeutic categories: General medicines (covering NSAIDs, antibiotics, cardiovascular drugs, vitamins, dermatological products, and more), Oncology & Biotech (including targeted therapies like sotorasib/Sotakras, immunotherapy drugs, and biosimilars like pembrolizumab and filgrastim), and Hormone products. The company has manufacturing facilities including Solid Unit, Sterile Unit, Oncology & Biotech, and Hormone Unit. Notable first-in-Bangladesh products include Dexilend, Dementa, Elipta, Ertoxa, Semaglo (semaglutide), and Vonolend (vonoprazan). Ziska exports specialty products including targeted oncology therapies (Palbociclib, Selpercatinib, Lenvatinib, Sotorasib) and operates global operations with presence in multiple countries.

Differentiator

Problem solved

Functional benefit

Products and services

• Dementa (Donepezil)

Quantifiable outcome

• 218+ pharmaceutical products in portfolio
• +2 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Amgen Inc.coreOthersZiska Pharmaceuticals is identified alongside Amgen Inc., Everest Pharmaceuticals Inc., and Lucius Pharmaceutical Co. Ltd. as major companies in the sotorasib tablets market. This indicates competitive positioning in the same therapeutic area rather than a formal partnership.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Eskayef Pharmaceuticals: Bangladeshi manufacturer producing branded generics, biologics, and specialty products with growing international presence; similar therapeutic mix and emerging-market export orientation to Ziska.
• Square Pharmaceuticals: Bangladesh's largest pharmaceutical company; manufactures a broad range of generics and specialty products for domestic and export markets and is the closest head-to-head peer to Ziska in scale, therapeutic breadth, and export orientation.
• ACI Limited (Pharma Division): Bangladesh conglomerate with a sizable pharmaceutical division covering generics, specialty, and consumer health; comparable to Ziska as a domestic peer operating across multiple therapy areas.
• Incepta Pharmaceuticals: Bangladesh-based manufacturer with a large product portfolio spanning oncology, biologics, hormones, and sterile injectables; closely comparable to Ziska on specialized manufacturing units and therapeutic diversification.
• ACME Laboratories: Bangladesh-based pharmaceutical manufacturer with a broad portfolio including oncology, hormone, and sterile products; comparable to Ziska on multi-unit manufacturing and therapeutic diversification.
• Drug International Limited: Bangladeshi generic and specialty pharma manufacturer with domestic and export operations; relevant peer to Ziska in product breadth and emerging-market positioning.
• Beximco Pharmaceuticals: Leading Bangladeshi exporter of generics and specialty pharmaceuticals with significant US FDA-approved operations; directly comparable to Ziska on therapeutic breadth, export focus, and emerging-market specialty positioning.
• Renata Limited: Diversified Bangladeshi pharma and animal-health company producing branded generics, hormones, and specialty products for domestic and international markets; comparable to Ziska on portfolio breadth and branded-generic positioning.

Broad incumbents

• Amgen: Originator of sotorasib (Lumakras) and a global biopharma incumbent in oncology and biologics; named alongside Ziska in the sotorasib market and the most direct innovator competitor in Ziska's export oncology book.
• Cipla: Indian multinational generic and specialty pharma with strong oncology, respiratory, and biosimilar portfolios across emerging and regulated markets; relevant incumbent comparable on therapeutic breadth and global export footprint.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/embed/_097lOYCahQ
• Facebookfacebook.com/ziskapharmaceuticalsltd
• LinkedInlinkedin.com/company/ziska-pharmaceuticals-limited
• Xx.com/ziska_pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ziska Pharmaceuticals